Skip to main content

Home/ Dr. Goodyear/ Group items tagged WHI

Rss Feed Group items tagged

Nathan Goodyear

JAMA Network | JAMA | Menopausal Hormone Therapy and Health Outcomes During the Interve... - 0 views

  •  
    This study cannot make the conclusion AT ALL.  They claim to say hormones should not be used to prevent chronic disease. Yet, the study they use to support this statement, the WHI, did not look at hormones.  The WHI looked at premarin and medroxyprogesterone acetate, a progestin.  They are not the hormones the body makes. Second, the WHI looked at women that were 6 years postmenopausal, on average, and then they added in bad drugs, disguised as hormone like, and then were dosed high.   If one desires to truly make a statement of prevention, one needs to pre-empt testing and therapy before disease.  Additionally, the study needs to match the hormones needed at the right physiologic level in the right balance.   One must also ensure proper hormone metabolism and know hormone receptor status.  This study does non of the above and the conclusion of this study is irrelevant.  In fact, I think the authors of this study have undergone scientific malpractice in their conclusions.
Nathan Goodyear

OASIS - 0 views

  •  
    I look forward to the published results of this study as this abstract references the WHI as the "same entry" criteria.  I imagine the HRT would be the same too, but will wait to see.  There is a serious problem with proper reporting of synthetic estrogens as bioidentical estrogens and synthetic progestins as bioidentical progesterone;  Also, what is the dosage. Most individuals are massively overdosed.  This study was said to be a "landmark".  Could just be don't use synthetic hormones: which is what the WHI said.
Nathan Goodyear

JAMA Network | JAMA | Conjugated Equine Estrogens and Incidence of Probable D... - 0 views

  •  
    This was the WHI review of data as it pertains to dementia and cognitive decline in women.  The take home here is that the data provides little evidence for premarin with or without medroxyprogesterone acetate in > 65 for prevention of dementia.  However, this is in women > 65 and studies show that younger women do indeed receive benefit, especially in those with early ovary removal.  Another point here, MPA (medroxyprogesterone acetate) increases cognitive decline.  Just don't take MPA, it is a bad drug all the way around!
Nathan Goodyear

The mortality toll of estrogen avoidance:... [Am J Public Health. 2013] - PubMed - NCBI - 0 views

  •  
    Yale study finds estrogen therapy in improves health in women ages 50-59.  The problems with hormone therapy is synthetics and overdosing.  The problem with the WHI was they used medroxy progesterone acetate--a synthetic progestin.   That is not progesterone.  This study estimated that 91,000 + died due to the uneducated view that estrogen HRT is dangerous.  What is dangerous is leaving the HRT and BHRT recommendations to those with conflicts of interest and a lack of knowledge of the science.
Nathan Goodyear

Hormone Therapy, Estrogen Metabolism, and Risk of Breast Cancer in the Women's Health I... - 0 views

  • These results demonstrate that although 16α-OHE1 was increased more by E+P than by E-alone, the increase in the 2:16 ratio was similar for both HT regimens, due to ~4-fold greater increase in 2OHE-1 than 16α-OHE1 for both HT regimens
  • baseline and 1 year change in 16α-OHE1 showed little relationship to incident breast cancer
  • higher baseline 2-OHE1 and the 2:16 ratio were modestly associated with higher odds of incident breast cancer, but larger 1 year increase in 2-OHE-1 and the 2:16 ratio were also weakly associated with lower odds of breast cancer
  •  
    Good review of the data from the WHI-HT on estrogen metabolites and breast cancer risk.  Increased 2-OHestrone and 2:16 ratio without statistical significance reached.
Nathan Goodyear

JAMA Network | JAMA: The Journal of the American Medical Association | Low-Fat Dietary ... - 0 views

  •  
    large study of 50,000 postmenopausal women found no significant reduction in CVD with a low fat diet.  The mean dietary time period was 8 years.
Nathan Goodyear

JAMA Network | JAMA | Estrogen Plus Progestin and the Incidence of Dementia a... - 0 views

  •  
    Estrogen with progestin worsens cognitive decline in women >65.  Little can be taken from this study other than, medroxyprogesterone acetate is a bad drug and should not be given to women for any purpose, especially in those >65.  One wonders if bioidentical, physiologic hormone replacement would have the same effect?  I doubt it.  The likely negative impact of hormones on the brain in women >65 is due to the negative effects of MPA, the change in inflammatory cytokines, and the change in receptors.
Nathan Goodyear

JAMA Network | JAMA | Effects of Conjugated Equine Estrogen in Postmenopausal... - 0 views

  •  
    Premarin increases the risk of stroke in postmenopausal women.  The risk of hip fracture was reduced and no change in Coronary Heart disease was found.
1 - 8 of 8
Showing 20 items per page